Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

NCT ID: NCT01346969

Last Updated: 2021-09-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-01

Study Completion Date

2012-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will investigate the efficacy of various doses and regimens of EXC 001 in reducing skin scarring in subjects undergoing revision of scars from prior surgery. The study will also evaluate the safety and tolerability of EXC 001 and placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Reduction in Hypertrophic Skin Scarring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Group Type ACTIVE_COMPARATOR

EXC 001

Intervention Type DRUG

Single-dose administered by injection four different times

Group 2

Group Type PLACEBO_COMPARATOR

EXC 001

Intervention Type DRUG

Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1

Group 3

Group Type PLACEBO_COMPARATOR

EXC 001

Intervention Type DRUG

Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2

Group 4

Group Type PLACEBO_COMPARATOR

EXC 001

Intervention Type DRUG

Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EXC 001

Single-dose administered by injection four different times

Intervention Type DRUG

EXC 001

Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1

Intervention Type DRUG

EXC 001

Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2

Intervention Type DRUG

EXC 001

Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have previous had breast surgery resulting in unacceptable scars.
* Subject has chosen to have breast scars revised.
* Subject must not be pregnant or lactating.

Exclusion Criteria

* Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or lactating.
* Participation in another clinical trial within 30 days prior to the start of the study.
* Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skin Deep Laser Medical Spa

Pasadena, California, United States

Site Status

Bright Health Physicans Plastic Surgery and Aesthetic Medicine

Whittier, California, United States

Site Status

Altus Research

Lake Worth, Florida, United States

Site Status

Bayside Ambulatory Center

Miami, Florida, United States

Site Status

Aesthetic Plastic Surgery Miami

Miami, Florida, United States

Site Status

Body Aesthetic Plastic Surgery

St Louis, Missouri, United States

Site Status

New Jersey Plastic Surgery

Montclair, New Jersey, United States

Site Status

Mark L. Jewell,MD Surgery Center

Eugene, Oregon, United States

Site Status

Connall Consmetic Surgery

Tualatin, Oregon, United States

Site Status

Endeavor Clinical Trials,P.A.

San Antonio, Texas, United States

Site Status

Texas Plastic Surgery

San Antonio, Texas, United States

Site Status

BAXTER Plastic Surgery

Mountlake Terrace, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B5301004

Identifier Type: OTHER

Identifier Source: secondary_id

EXC 001-204

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Macrolane Retrospective Study
NCT01223963 COMPLETED